BAX Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of -18.6% compared to Baxter International's net margin of 5.86%. Baxter International's return on equity of -8.24% beat Becton Dickinson &'s return on equity of 6.75%.

Baxter International has a consensus price target of $39.74, signalling upside risk potential of 42.75%. On the other hand Becton Dickinson & has an analysts' consensus of $275.03 which suggests that it could grow by 36.3%. Given that Baxter International has higher upside potential than Becton Dickinson &, analysts believe Baxter International is more attractive than Becton Dickinson &.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.131%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.31%. Becton Dickinson & offers a yield of 1.97% to investors and pays a quarterly dividend of $1.04 per share. Baxter International pays -90.91% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.8B, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. Baxter International's net income of -$512M is lower than Becton Dickinson &'s net income of $303M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Becton Dickinson &'s PE ratio is 33.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.11x versus 2.84x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -18.6% compared to Baxter International's net margin of 12.41%. Baxter International's return on equity of -8.24% beat Boston Scientific's return on equity of 8.96%.

Baxter International has a consensus price target of $39.74, signalling upside risk potential of 42.75%. On the other hand Boston Scientific has an analysts' consensus of $115.00 which suggests that it could grow by 22.77%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.31%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International pays -90.91% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Baxter International quarterly revenues are $2.8B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Baxter International's net income of -$512M is lower than Boston Scientific's net income of $566M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Boston Scientific's PE ratio is 74.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.11x versus 8.31x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -18.6% compared to Baxter International's net margin of 26.88%. Baxter International's return on equity of -8.24% beat ResMed's return on equity of 25.56%.

Baxter International has a consensus price target of $39.74, signalling upside risk potential of 42.75%. On the other hand ResMed has an analysts' consensus of $267.15 which suggests that it could grow by 24.85%. Given that Baxter International has higher upside potential than ResMed, analysts believe Baxter International is more attractive than ResMed.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.31%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Baxter International pays -90.91% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.8B, which are larger than ResMed quarterly revenues of $1.3B. Baxter International's net income of -$512M is lower than ResMed's net income of $344.6M. Notably, Baxter International's price-to-earnings ratio is 167.20x while ResMed's PE ratio is 25.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.11x versus 6.41x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -18.6% compared to Baxter International's net margin of 8.48%. Baxter International's return on equity of -8.24% beat Stryker's return on equity of 15.22%.

Baxter International has a consensus price target of $39.74, signalling upside risk potential of 42.75%. On the other hand Stryker has an analysts' consensus of $422.33 which suggests that it could grow by 20.57%. Given that Baxter International has higher upside potential than Stryker, analysts believe Baxter International is more attractive than Stryker.

Baxter International has a beta of 0.645, which suggesting that the stock is 35.462% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Baxter International has a quarterly dividend of $0.17 per share corresponding to a yield of 3.31%. Stryker offers a yield of 0.94% to investors and pays a quarterly dividend of $0.84 per share. Baxter International pays -90.91% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Baxter International quarterly revenues are $2.8B, which are smaller than Stryker quarterly revenues of $6.4B. Baxter International's net income of -$512M is lower than Stryker's net income of $546M. Notably, Baxter International's price-to-earnings ratio is 167.20x while Stryker's PE ratio is 45.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International is 1.11x versus 5.98x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.